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Despite all modern advances in medicine, an effec-
tive drug treatment of obesity has not been found
yet. Discovery of leptin two decades ago created
hopes for treatment of obesity. However, develop-
ment of leptin resistance has been a big obstacle,
mitigating a leptin-centric treatment of obesity.
Here, by using in silico drug-screening methods,
we discovered that Celastrol, a pentacyclic triter-
pene extracted from the roots of Tripterygium
Wilfordi (thunder god vine) plant, is a powerful anti-
obesity agent. Celastrol suppresses food intake,
blocks reduction of energy expenditure, and leads
to up to 45% weight loss in hyperleptinemic diet-
induced obese (DIO) mice by increasing leptin sensi-
tivity, but it is ineffective in leptin-deficient (ob/ob)
and leptin receptor-deficient (db/db)mouse models.
These results indicate that Celastrol is a leptin sensi-
tizer and a promising agent for the pharmacological
treatment of obesity.INTRODUCTION
In 2008, the World Health Organization (WHO) estimated that
1.4 billion adults worldwide were overweight; of these,
200 million men and 300 million women were obese (Finucane
et al., 2011). It is predicted that more than one billion people in
the world will be obese by 2030 (Kelly et al., 2008). Obesity is a
major cause for the development of debilitating conditions
such as type 2 diabetes, cardiovascular disease, hypertension,
and non-alcoholic steatohepatitis, all of which reduce life quality
as well as lifespan (Olshansky et al., 2005).
Nutritional and hormonal inputs from the periphery to the
central nervous system (CNS) are interpreted by a complex
neuronal circuitry that maintains energy balance in the organism
(Dietrich and Horvath, 2013; Myers et al., 2010). Leptin is an
adipocyte-derived hormone, which is the main messenger that
carries information about peripheral energy stores to the CNS
(Dietrich and Horvath, 2013; Myers et al., 2010). The historic
discovery of leptin by Friedman and co-workers two decades
ago opened a new chapter with regard to the possibility of
developing a treatment for obesity (Halaas et al., 1995; Zhang
et al., 1994). However, initial hopes for leveraging leptin’sanorectic effect for treating obesity quickly diminished, as it
became clear that, despite the presence of very high levels of
circulating leptin in murine models of obesity and in obese
humans, the hormone is ineffective in creating satiety and
suppressing food intake (Considine et al., 1996; Frederich
et al., 1995). Furthermore, while exogenously administered leptin
does suppress food intake and reduce body weight in lean mice,
it is ineffective in diet-induced obese (DIO) mice (Halaas et al.,
1997). These findings led to the notion that obesity is a condition
of leptin resistance, or leptin insensitivity (Considine et al., 1996;
Frederich et al., 1995). Despite long-standing research efforts,
drugs that can alleviate leptin resistance have not yet been
found.
Perturbations of endoplasmic reticulum (ER) homeostasis,
predominantly triggered by the accumulation of unfolded pro-
teins, lead to the development of a condition referred to as ER
stress (Lee and Ozcan, 2014; Park and Ozcan, 2013; Ron and
Walter, 2007) and activate a complex signaling cascade called
the unfolded protein response (UPR) (Ron and Walter, 2007).
We have previously shown that ER stress is tightly linked to the
pathophysiology of several metabolic diseases (Ozcan et al.,
2004, 2006), including obesity (Ozcan et al., 2004, 2009). Previ-
ous observations documented that increased ER stress in the
brain plays a central role in the development of leptin resistance
and, consequently, of obesity (Ozcan et al., 2009). Specifically,
depletion of X-box binding protein 1 (XBP1) from neurons leads
to increased ER stress, severe hyperleptinemia, leptin resis-
tance, and obesity (Ozcan et al., 2009). On the other hand, over-
expression of spliced form of XBP1 (XBP1S) in in vitro and in vivo
settings increases leptin sensitivity (Ozcan et al., 2009; Williams
et al., 2014).
In parallel with these findings, chemical chaperones such
as 4-phenyl butyrate (4-PBA) and tauroursodeoxycholic acid
(TUDCA), which are agents that improve ER function and
decrease ER stress, increase leptin sensitivity, although rather
weakly (Ozcan et al., 2006, 2009).
Experimental findings indicate that the use of different
manipulations that interfere with the ER system with the goal of
reducing ER stress could have distinct outcomes. For example,
transcription factors, such as XBP1S or activating transcription
factor-6 (ATF6), increase the expression of chaperones and
reduce ER stress (Ron and Walter, 2007), while expression of
sarco(endo)plasmic reticulum Ca2+ ATPase 2b (SERCA2B) in
the liver reduces ER stress (Park et al., 2010) without altering
the expression of chaperones. In both situations, ER stress is
reduced, but in one case it is accompanied by upregulation ofCell 161, 999–1011, May 21, 2015 ª2015 Elsevier Inc. 999
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Figure 1. Identification of Celastrol as a Potential Anti-Obesity Molecule
(A) Flow chart depicting the process for obtaining gene expression signatures from the liver to identify potential anti-obesity compounds. C57BL/6Jmice (left flow
chart) or ob/obmice (middle flow chart) were orally treated with either vehicle or 4-PBA (n = 3 for each group) and ob/obmice injected with Ad-XBP1S or Ad-LacZ
(n = 3 for each group) (right flow chart).
(B) Heatmaps representing the selected 50 upregulated (blue) and 50 downregulated (red) genes—vehicle versus 4-PBA from lean mice (left), vehicle versus 4-
PBA from ob/obmice (middle), and Ad-XBP1S versus Ad-LacZ from ob/obmice (right). Microarray chip probe and the corresponding gene identifiers are listed
next to the heatmaps.
(C) Three-dimensional plot of the absolute enrichment scores obtained from CMAP using three different signatures. Each data point represents a small molecule.
Blue-to-red color codings represent low-to-high absolute product score.
(D) Formula used to calculate absolute enrichment score for individual small molecules in CMAP database.
(E) Distribution of the calculated absolute enrichment score of individual small molecules. The red dot represents Celastrol, and its chemical structure is shown in
the graph.
(F) Flow chart depicting the process used to obtain gene expression signatures in the hypothalamus. C57BL/6J mice were fed on either normal chow diet or
high-fat diet (HFD; n = 4 for each group) (left flow chart). DIOmice treatedwith either vehicle or 4-PBA or with TUDCA (right flow chart). Geometric means of 4-PBA
and TUDCA-induced changes in gene expression (RPBA and RTUDCA) were determined to obtain hypothalamic chaperone signature.
(legend continued on next page)
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chaperone expression, and in the other it is not. Furthermore,
chemical chaperones can decrease ER stress; however, this
reduction may be accompanied by a decreased chaperone
expression (de Almeida et al., 2007). Thus, depending on the
specificmanipulation, the shift from a stressed to a non-stressed
ER could have different homeostatic outcomes, including
increased, unaltered, or decreased expression of ER stress-
related genes. This means that homeostatic ER conditions
can manifest along with the up or downregulation of the same
set of genes.
In our current work, we used an alternative approach to
identify small molecules that could increase leptin sensitivity
and treat obesity. We reasoned that, rather than targeting a
single molecule in the UPR-signaling pathway, we should utilize
the outcome of a variety of interventions that reduce ER stress;
and that we should use these outcomes of homeostatic ER
conditions to search for small molecules that can create the
same outcomes.
Connectivity map (CMAP) comprises a database and associ-
ated software that is produced by the Broad Institute and is
composed of whole-genome gene expression profiles derived
from human cell lines that were treated with more than a
thousand small molecules (Lamb et al., 2006). The software
can compare two sets of genes that are upregulated and down-
regulated in a specific condition with the whole CMAP database.
CMAP can thus be utilized to identify small molecules that create
gene expression patterns similar to those being searched for.
In our current work, we have created gene expression signa-
tures by utilizing the microarray data obtained following various
interventions to relieve ER stress in a number of tissues;
we then used these signatures to identify small molecules that
can increase leptin sensitivity and thereby offer a treatment for
obesity.
RESULTS
Use of Transcriptional Profiling to Identify
Small-Molecule Leptin Sensitizers
4-PBA reduces ER stress, even in the absence of XBP1 (Ozcan
et al., 2006), suggesting that each manipulation establishes ER
homeostasis via independent pathways. Based on this, we first
sought to determine the whole-genome gene expression profile
of livers that were obtained either from 4-PBA-treated mice or
from obese mice with liver-specific overexpression of XBP1S.
These expression profiles from liver were selected for two
reasons: (1) both of these conditions were representation of
a homeostatic ER state that had been established on a previ-
ously stressed condition through different mechanisms, and (2)
CMAP is based on data obtained from cell lines, which led us(G) Heatmap representing the selected 50 upregulated and 50 downregulated hyp
and TUDCA.
(H) Distribution of individual small molecules in CMAP depending on their absolu
(y axis: obesity enrichment score) and hypothalamic chaperone signature (x axis
(I) Distribution of hypothalamic absolute product scores of individual small molec
(J) The dot distribution of absolute product scores of the liver and the hypothala
(K) Distribution of the final scores calculated as a product of liver and hypothalam
Red dot represents Celastrol in (H-K). See also Figure S1.to reason that inclusion of liver microarrays would increase our
chances of identifying small molecules, because hypothalamus
is a highly specialized tissue.
To determine the 4-PBA-regulated transcriptome, we treated
ob/ob mice and their lean controls with either vehicle or 4-PBA
and then dissected out the liver from both groups and extracted
RNA for microarray analysis. In parallel, to identify the XBP1S-
regulated expression liver profile in obese mice, XBP1S-ex-
pressing adenovirus (Ad-XBP1S) or a control LacZ-expressing
adenovirus (Ad-LacZ) was injected into the tail vein of ob/ob
mice, and subsequently, the liver RNA was isolated and pre-
pared for microarray analysis.
We first determined the fold changes in levels of gene expres-
sion in livers from 4-PBA- versus vehicle-treated lean or ob/ob
mice and then performed the same analysis in XBP1S- versus
LacZ-expressing ob/ob mice. From each of the above three
experimental groups, we selected 50 upregulated and 50 down-
regulated genes (Figures 1A and 1B and Data S1) and converted
the mouse gene identifiers for our probe annotations to human
gene identifiers. The final lists of genes that were analyzed as
gene signatures in CMAP were of varying lengths due to this
conversion (Figure S1).
We first obtained individual enrichment scores for the
three gene signatures (fold changes created by XBP1S over-
expression in the liver of obese mice, following 4-PBA treat-
ment in the liver of lean or obese mice). However, as discussed
above, relieved ER stress can manifest as increased or
decreased expression of related genes—in other words, each
distinct condition of relieved ER stress may be positively or
negatively correlated to levels of gene expression, which would
correspond to positive or negative enrichment scores, respec-
tively. Therefore, we calculated the absolute values of enrich-
ment scores and used the absolute enrichment score in our
analysis.
At the outset, we first analyzed the absolute enrichment score
of CMAP results that were obtained by using the gene array of
lean mice, treated with 4-PBA. The results from this analysis
led to identification of Celastrol as themost promising candidate,
which initiated the research on Celastrol (Figure 1C). Subse-
quently, after obtaining the distribution of the absolute enrich-
ment scores for all small molecules in CMAP for the three gene
signatures (Figure 1C), we also used a new method to rank
the small molecules with a single dimensional metric, which is
calculated from the three absolute enrichment scores (Fig-
ure 1D); this metric was defined as the ‘‘absolute product score,’’
and it represents the value of the highest score from the combi-
nation of the three enrichment scores.
This algorithm also yielded Celastrol as the top-ranking small
molecule and proved the initial observations (Figure 1E).othalamic genes obtained. (Left) Lean versus DIO; (right) vehicle versus 4-PBA
te enrichment scores obtained by analysis of hypothalamic obesity signature
: chaperone enrichment score).
ules obtained from CMAP database.
mus. Each data point represents an individual small molecule.
us absolute product scores.
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We subsequently used expression profiles from the hypothal-
amus (Data S1), a tissue that is vital for leptin action and is the
major site for leptin resistance. We first compared the negative
or positive alterations in the gene expression profile of the
hypothalamus of DIO mice to those of lean controls. The 50
most up- and downregulated genes in the hypothalami of DIO
versus lean mice were used to generate an obesity-related
hypothalamic gene expression signature, referred to as the
hypothalamic obesity signature (Figures 1F and 1G).
Next, to determine chemical chaperone-induced changes in
the pattern of gene expression in the hypothalamus, DIO mice
were divided into three subgroups and were treated with saline,
4-PBA, or TUDCA for 7 days. Fold changes (relative to control) in
the levels of gene expression in the hypothalami of 4-PBA- or
TUDCA-treated mice were calculated (Data S1). To generate
one signature related to chemical chaperones, we took the
geometric mean of fold changes for each gene in the 4-PBA-
and TUDCA-treated groups (Figures 1F and 1G); we defined
these as the hypothalamic chaperone signatures (Figure 1G).
The absolute value of the enrichment scores for each of the
two signatures was calculated by CMAP (Figure 1H). The abso-
lute product score again ranked Celastrol as one of the top
compounds in the database (Figure 1I). As seen from the com-
bined distribution of the absolute product scores for the liver
and hypothalamus shown in Figure 1J, Celastrol was the high-
est-scoring small molecule (once the absolute product scores
of liver and hypothalamus experiments had been further
analyzed by multiplication of these two scores) (Figure 1K).
Celastrol is a pentacyclic triterpene extracted from the
Tripterygium Wilfordi (thunder god vine) plant (Corson and
Crews, 2007). The plant itself has a long history of human use
in traditional Chinese medicine, typically for rheumatoid arthritis,
but we have found no reports of Celastrol itself having been
administered to humans. Celastrol reportedly has anti-cancer
effects both in vitro and in vivo (Corson and Crews, 2007).
Celastrol Ameliorates Obesity in Diet-Induced
Obese Mice
DIOmice were either treated with vehicle or Celastrol intraperito-
neally. Administration of Celastrol significantly reduced the
body weight of DIO mice, from 47.53 ± 1.0 g to 35.43 ± 0.97 g
(on day 1 versus day 15 of treatment, p < 0.001), after which
the body weights were stabilized. At the end of the third week,
body weight of Celastrol-receiving DIO mice reached 34.38 ±
1.06 g (Figure 2A), corresponding to a 27.67% ± 1.48% weight
loss relative to their initial weights (Figure 2B). The body weight
of vehicle-treated control mice showed no alterations. During
the first week of trial, the daily food intake for the control group
was 2.06 ± 0.11 g and was reduced to 0.43 ± 0.12 g in the Celas-
trol-treated group, corresponding to a 79% reduction (Figures
2C and S2A). Reduction in food intake seen during the first
week gradually disappeared and was normalized to control
levels by the end of the 3-week period (data not shown). This
increase in the food intake during the last week was inversely
correlated to the levels of circulating leptin, which steadily
decreased and reached close-to-lean levels by the end of the
3-week treatment period (Figure 2D). Celastrol treatment did
not alter the lean mass of DIOmice relative to the vehicle-treated1002 Cell 161, 999–1011, May 21, 2015 ª2015 Elsevier Inc.control group (Figure 2E). However, the fat percentage of
Celastrol-treated mice was significantly (41.5%) lower than
that of vehicle-treated group (Figure 2F).
As opposed to DIO mice, lean mice have very low levels of
circulating leptin levels. Based on the fact that Celastrol-
induced weight loss is much more potent at the beginning of
the treatment period, when the DIO mice are hyperleptinemic,
and that the response of the mice to Celastrol ceases as plasma
leptin levels drop, we reasoned that Celastrol would have mini-
mal effects in lean mice. Consistent with our expectations, Ce-
lastrol administration did not significantly reduce the body
weight of lean mice at doses that were effective in DIO mice
(Figure 2G and 2H). On the contrary, Celastrol-treated lean
mice continued to gain weight as the control group (Figure 2G
and 2H). Furthermore, the food intake of vehicle- or Celastrol-
treated lean mice was the same (Figures 2I and S2B), and
plasma leptin levels of lean mice were not altered during the
treatment period (Figure 2J). We also did not detect any
changes in the lean mass (Figure 2K) or fat percentage (Fig-
ure 2L) of lean mice treated with Celastrol. These findings further
supported the possibility that Celastrol is a leptin sensitizer.
Furthermore, we have also administered vehicle or Celastrol to
WT mice that were kept on chow or high-fat diet (HFD) in two
different cohorts for 195 and 216 days (Figures S2I and S2J).
This long-term chronic administration has shown that, first,
Celastrol does not create toxic effect in mice, and second, it
also suppresses development of obesity.
Celastrol Is a Leptin Sensitizer
If Celastrol is, indeed, a true leptin sensitizer, it should either have
no effect or a minimal effect in ob/ob or db/db mice, both of
which lack leptin action. We therefore tested the effect of
Celastrol on ob/ob and db/db mice. Vehicle-treated db/db
mice gained weight during the course of the experiment (Figures
3A and 3B). Importantly, treatment of db/db mice with Celastrol
did not induce any weight loss, and the mice gained similar
amounts of weight as did the vehicle-treated mice (Figure 3A);
in fact, at the end of the treatment period, the body weight of
db/db mice receiving Celastrol treatment was 14.01% ± 0.68%
heavier than their initial body weight (Figure 3B). The food intake
(Figures 3C and S2C), lean mass (Figure 3D), fat percentage
(Figure 3E), and leptin levels (Figure 3F) of the vehicle- versus
Celastrol-treated db/db mice were unchanged between the
two groups.
We next investigated the effect of Celastrol on ob/ob mice.
Vehicle-treated ob/ob mice continued to gain weight (Figures
3G and 3H). Administration of Celastrol to ob/ob mice led to a
slight decrease in the body weight during the first week of
treatment, but this decrease was rapidly compensated, and no
significant difference in the body weights of animals in the two
groups was detected after the trial (Figure 3G). In fact, there
was a slight increase in their body weight at the end of the trial
(Figure 3H). Food intake of the ob/ob mice showed a slight
yet significant decrease during the first week in the majority of
the independent experimental cohorts (data not shown), but
this reduction, despite continuing presence of obesity of ob/ob
mice, was rapidly normalized in the second week of treatment
and thereafter (Figures 3I and S2D). Furthermore, lean mass
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Figure 2. Celastrol Acts as an Anti-Obesity
Agent on High-Fat Diet-Induced Obese Mice
HFD-fed obese mice (A–F) or 10-week-old C57BL/
6J lean mice (G–L) were daily treated with vehicle
or Celastrol (100 mg/kg) intraperitoneally (i.p.) for
3 weeks.
(A and B) (A) Body weight (g) (n = 5 for each group)
and (B) percent decrease (%) in body weight in DIO
mice during the treatment.
(C) Three-day average of food intakes (g) of DIO
mice during the first week of treatment. Experi-
ments were repeated in more than three indepen-
dent cohorts.
(D) Plasma leptin levels of vehicle (n = 8) or Celastrol
(n = 8; 100 mg/kg) treated DIO mice during 3 weeks
of treatment.
(E and F) Dual-energy X-ray absorptiometry (DEXA)
scans showing (E) leanmass (g) and (F) fat mass (%)
of DIO mice after 3 weeks of treatment (n = 6 per
each group). DEXA scans were repeated in more
than three independent cohorts.
(G) Body weight (g) (n = 5 for each group) and (H)
percent decrease (%) in body weight of lean mice
during the treatment.
(I) Three-day average food intakes of the lean mice
during the first week of treatment. Experiments in
(G-I) were repeated three times.
(J) Plasma leptin levels of leanmice after 3 weeks of
treatment (n = 11 for each group).
(K) Lean mass (g) and (L) fat mass percent (%) of
lean mice after 3 weeks treatment (n = 6 per each
group).
Error bars are represented as mean ± SEM.
p values were determined by two-way ANOVA
(A and B) or Student’s t test (*p < 0.05, **p < 0.01,
***p < 0.001). See also Figures S2 and S7.(Figure 3J) and the fat percentage (Figure 3K) of ob/obmice were
also not affected by Celastrol treatment.
Oral Administration of Celastrol Also Has a Strong Anti-
Obesity Effect in DIO Mice
To investigate whether Celastrol also exerts its anti-obesity effect
when it is administered orally, we administered Celastrol by
oral gavage. Figures 4A and 4B show that oral administration of
vehicle for 3 weeks did not alter the body weights of DIO mice.
However, oral administration of Celastrol had a robust effect on
body weight, reducing it from 49.85 ± 0.97 g on day 1 to 27.15 ±
1.37 g on day 22 (p < 0.001), corresponding to a 45.4% ± 3.46%
decrease relative to their initial body weights (Figure 4B). The
food intake of DIO mice was also significantly reduced when
compared to the vehicle-treated group (Figures 4C and S2E).
Oral administration of Celastrol to lean (Figures 4D–4F and S2F),
db/db (Figures 4G–4I and S2G), and ob/ob (Figures 4J–4L and
S2H) mice did not induce a significant change in body weight
or food intake compared to their respective control groups.Cell 161, 999–10Celastrol Potentiates Leptin’s Effect
We reasoned that administration of exog-
enous leptin to lean mice that were pre-
treated with Celastrol should create a
stronger outcome compared to adminis-tration of leptin to a vehicle-pretreated control if the absence of
effect of Celastrol in lean mice were due to low levels of circu-
lating leptin. We thus administered lean mice either vehicle or
Celastrol and, subsequently, injected saline or a bolus dose of
leptin to each group. Figure 5A shows that leptin administration
to leanmice (Vehicle+Leptin) led to a significant decrease in food
intake (corresponding to a 41% decrease in Vehicle+Leptin over
the Vehicle+Saline group). Lean mice that received Celastrol
plus leptin consumed less food than any of the other groups;
this leptin-induced suppression of food intake in the presence
of Celastrol corresponded to a 62% decrease when compared
to the food intake of the Celastrol+Saline group (Figure 5A).
Leptin administration to lean mice (Vehicle+Leptin) resulted in
a significant decrease in the body weight (Vehicle+Saline versus
Vehicle+Leptin, p < 0.01), but Celastrol alone (Celastrol+Saline)
did not cause a significant change in the body weight of lean
mice (Vehicle+Saline versus Celastrol+Saline, p = 0.10). Leptin
administration to lean mice that were pre-treated with Celastrol
led to a 1.87 ± 0.32 g loss in body weight. These results show11, May 21, 2015 ª2015 Elsevier Inc. 1003
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Figure 3. Celastrol Is Minimally Effective in
db/db or ob/ob Mice
Eight-week-old male db/db (A–F) or ob/ob mice
(G–K) were subjected to a 3-week treatment of
vehicle or Celastrol (100 mg/kg) (daily, i.p.).
(A and B) (A) Body weight (g) and (B) percent
decrease in body weight of db/db mice during the
treatment (n = 5 for each group).
(C) Three-day average of food intakes of db/db
mice during the first week of treatment. Experi-
ments were repeated in three independent cohorts.
(D and E) (D) Lean mass (g) and (E) fat percentage
(%) of db/dbmice determined by DEXA scans after
3 weeks treatment (n = 5 for each group). DEXA
scans were done on two different cohorts.
(F) Plasma leptin levels before and 12 and 24 days
after Celastrol treatment (n = 5 for each group).
(G and H) (G) Body weight (g) and (H) percent
decrease in body weight of ob/ob mice during the
treatment (n = 8 for vehicle and n = 10 for Celastrol
group).
(I) Three-day average of food intake of ob/ob mice
during the second week of the treatment.
(J) Lean mass (g) and (K) fat percentage (%) on
3 weeks of treatment (n = 6 for vehicle and n = 5 for
Celastrol group) measured by DEXA scan. DEXA
scans were performed in two different cohorts.
Error bars are represented as mean ± SEM.
p values were determined by Student’s t test.
See also Figures S2 and S7.that the average leptin-induced reduction in body weight for
Celastrol-pretreated mice was 1.63 g, in contrast to the 0.63 g
decrease in mice that were pre-treated with vehicle, suggesting
that Celastrol potentiates the effect of leptin in reducing weight
in lean mice (Figure 5B).
To investigate whether Celastrol also acutely potentiates the
anorectic and weight-reducing effects of exogenous leptin in
DIO mice, we tested the response of these animals to leptin in
the presence and absence of Celastrol. Administration of leptin
to DIO mice did not significantly alter their food intake, compared
to thecontrol group.Celastrol treatment alonedecreased the food
intake of DIO mice (Vehicle+Saline versus Celastrol+Saline, p <
0.001), and administration of leptin to DIO mice that were
pre-treatedwithCelastrol (Celastrol+Leptin) led toa further reduc-
tion in food intake relative to the Celastrol+Saline group (p < 0.01)
(Figure5C). Furthermore, treatmentwith leptin alonedidnot signif-
icantly change the body weights of DIO mice (Figure 5D), while
Celastrol treatment led to a 0.86 ± 0.15 g decrease in bodyweight
of DIO mice (Vehicle+Saline versus Celastrol+Saline, p < 0.001)1004 Cell 161, 999–1011, May 21, 2015 ª2015 Elsevier Inc.(Figure 5D). Administration of leptin in the
presence of Celastrol (Celastrol+Leptin
group) documented that Celastrol further
augmented the negative effect of leptin on
body weight; DIO mice in the Celastrol+
Leptin group lost 1.42 ± 0.19 g of body
weight, which was significantly lower than
all of the other groups (Figure 5D).
To provide additional physiological
proof that Celastrol acts as a leptin sensi-tizer, we tested whether additional Celastrol treatment further
upregulates leptin action in ob/ob mice. As shown in Figure 5E,
low dose of leptin by itself created no significant differences in
the body weight gain of the ob/obmice. However, administering
the same dose of leptin in the presence of Celastrol led to a
pronounced weight loss during the course of the treatment,
with ob/ob mice losing 15.36% ± 2.61% of their initial body
weight (p < 0.001 versus all other groups) (Figure 5E). Co-admin-
istration of leptin and Celastrol led to a 2-fold greater suppres-
sion of food intake (leptin-induced % suppression of food intake
in vehicle versus Celastrol groups, p < 0.001), suggesting that
Celastrol potentiates the anorectic effect of leptin even in
ob/ob mice (Figure 5F).
Celastrol Activates the Hypothalamic Leptin
Receptor-Stat3 Pathway in DIO Mice
We next investigated the leptin receptor signaling network after
Celastrol treatment. To address whether Celastrol increases hy-
pothalamic leptin sensitivity, we analyzed how acute Celastrol
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Figure 4. Oral Administration of Celastrol
Reduces Body Weight and Food Intake of
DIO Mice
(A–C) DIO mice, (D–F) lean mice, (G–I) db/db, or
(J–L) ob/ob mice were subjected to oral adminis-
tration of vehicle (captisol) or Celastrol (10 mg/kg)
for 3 weeks.
(A and B) (A) Body weight (g) and (B) percent
decrease (%) in body weight of DIOmice during the
treatment.
(C) The average of 3-day food intake of DIO mice
during the first week of treatment. (n = 5 for vehicle
group and n = 4 for Celastrol group in A–C).
Experiments on DIO mice were independently
repeated twice.
(D and E) (D) Body weight (g) and (E) percent
decrease in body weight of lean mice during
Celastrol treatment.
(F) The averages of 3-day food intake (g) of the lean
mice during the first week of treatment. n = 5 for
each group in (D–F).
(G and H) (G) Body weight (g) and (H) percent
decrease in body weight of db/db mice during the
treatment.
(I) The average of 3-day food intake of db/db mice
during the first week of treatment. (n = 4 for vehicle
and n = 5 for Celastrol treatment in G–I).
(J and K) (J) Body weight (g) and (K) percent
decrease in body weight of ob/ob mice during
Celastrol treatment.
(L) The average of 3-day food intake (g) of ob/ob
mice during the first week of treatment (n = 5 for
each group in J–L).
Error bars are represented as mean ± SEM.
p values were determined by two-way ANOVA
(A and B) or Student’s t test (*p < 0.05, **p < 0.01,
***p < 0.001).administration influences leptin-stimulated STAT3Tyr705 phos-
phorylation in DIO mice at a time when the mice are still obese
and hyperleptinemic.
Injection of this hormone in vehicle-treated DIO mice did not
lead to a significant increase in STAT3Tyr705 phosphorylation
(Figures 6A and 6B), but Celastrol treatment alone did lead to a
significant increase in basal levels of STAT3Tyr705 phosphoryla-
tion in the hypothalamus (Figures 6A and 6B). However, when
leptin was administered to DIO mice that were pre-treated with
Celastrol, the levels of p-STAT3Tyr705 in the hypothalamus
increased even further (Figures 6A and 6B), indicating that
treatment of DIO mice, with even a single dose of Celastrol,
was sufficient to increase leptin sensitivity.
We next investigated the hypothalamic mRNA levels of
pro-opiomelanocortin (POMC), Agouti-related peptide (AGRP),
and Neuropeptide Y (NPY). Surprisingly, we did not find
any difference in the mRNA levels of POMC between vehicle
and Celastrol-treated mice (Figure 6C). Furthermore, we have
found that AGRP expression levels, completely contrary toCell 161, 999–10general expectations, were significantly
increased (Figure 6D). However, NPY
mRNA levels were not altered (Figure 6E).
In addition, suppressor of cytokine sig-naling 3 (SOCS3) expression level was significantly increased
in the Celastrol-treated DIO mice when compared with the
control group (Figure 6F).
Celastrol Reduces ER Stress in the Hypothalamus
We next investigated the effect of Celastrol on the status of
ER stress in the hypothalamus of DIO mice. Treatment of
mice with Celastrol led to a significant decrease in PERK
phosphorylation, indicating that Celastrol reduces ER stress
(Figures 6G and S3A–S3H). Moreover, we also treated tuber-
ous sclerosis complex 2 (TSC2) knock out (TSC2/) mouse
embryo fibroblasts (MEF) with Celastrol. TSC2/ cells were
previously shown to have intrinsic ER stress (Ozcan et al.,
2008). Treatment of TSC2/ cells with Celastrol has shown
that Celastrol also reduces PERK phosphorylation and, conse-
quently, ER stress in this in vitro system (Figure S3I). Further-
more, analysis of SERCA2B levels also showed a significant
reduction in the hypothalamus of Celastrol-treated mice (Fig-
ure 6H and 6I).11, May 21, 2015 ª2015 Elsevier Inc. 1005
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Figure 5. Celastrol Acts as a Leptin
Sensitizer
(A and B) Vehicle or Celastrol (150 mg/kg) were
administered to lean mice for 2 days, and each
group subsequently received either saline (n = 9 for
vehicle and n = 11 for Celastrol subgroup) or leptin
(n = 12 for each subgroup) (5 mg/kg). (A) Food intake
and (B) body weight change during 24 hr period
following saline/leptin injections. Experiments were
repeated in two independent cohorts.
(C and D) Vehicle (n = 12) or Celastrol (n = 10;
150 mg/kg) were administered to DIO mice for
2 days, and each group of mice received either
saline (n = 6 vehicle; n = 5 Celastrol) or leptin
(n = 6 vehicle; n = 5 Celastrol) (1 mg/kg). (C) Food
intake (g) and (D) body weight change (g)
during 16 hr period following saline/leptin injections.
These experiments were independently repeated
two times.
(E and F) ob/obmice were treatedwith either vehicle
(n = 9) or Celastrol (100 mg/kg, n = 9) for the next
5 days. For the next 1 week, each group of mice was
also treated with either saline or leptin (0.1 mg/kg)
(n = 5 saline and n = 4 leptin). (E) Percent decrease in
body weight. (F) Percent suppression of food
intake during leptin treatment. Experiments were
repeated in two independent cohorts. Error bars
are represented as mean ± SEM. p values were
determined by Student’s t test (*p < 0.05, **p < 0.01,
***p < 0.001).We next investigated the mRNA levels of XBP1S, various
ER chaperones, and mitofusins (MFN1 and MFN2). However,
we did not see any alterations in the mRNA levels of these genes
(Figures S3J and S3K).
Celastrol has been also suggested to inhibit NF-kB sig-
naling pathway (Lee et al., 2006). Determining the mRNA
levels of various target genes of NF-kB pathways showed
no difference in the hypothalamus of vehicle- or Celastrol-
treated mice (Figure S4A). Celastrol has also been proposed
as a heat-shock protein 90 kDa (HSP90) inhibitor (Hieronymus
et al., 2006). HSP70 protein level is an indicator of HSP90
activity, and inhibition of HSP90 leads to increase in HSP701006 Cell 161, 999–1011, May 21, 2015 ª2015 Elsevier Inc.protein levels (Neckers, 2007). However,
we did not find any increase in HSP70
protein levels—on the contrary, there
was a slight decrease. (Figures S4B
and S4C).
Energy Homeostasis inMice Treated
with Celastrol
Leptin is reported to maintain high-energy
expenditure even though it reduces food
intake (Halaas et al., 1995). Based on the
above data, we reasoned that Celastrol,
despite its robust effects on food intake
and body weight, would enhance energy
expenditure and lead to the utilization of
fat as the main energy source. We thus
measured metabolic parameters (energyexpenditure [EE] and respiratory exchange ratio [RER] and levels
of physical activity) in vehicle- and Celastrol-treated mice. No
differences were seen in EE between vehicle- and Celastrol-
treated groups in the dark cycle (Figure 7A and Data S2 and
S3). However, EE of the Celastrol-treated mice was higher in
the light cycle (Figure 7A and Data S2 and S3). Also, RER values
were significantly decreased in Celastrol-treated DIO mice in
both the dark and light cycles (Figure 7B and Data S2 and S3).
Levels of physical activity during the dark phase in DIO mice
were significantly reduced as a result of Celastrol administration,
but no differences were observed in the light phase (Figure 7C
and Data S2 and S4). It is possible that the reduced physical
A B C
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Figure 6. Celastrol Potentiates Leptin Signaling and Reduces ER Stress
(A and B) Vehicle or Celastrol (500 mg/kg) were administered to DIO. 15 hr later, each group of mice was treated with either saline or leptin (1 mg/kg) for 40min. (A)
Immunoblot analysis of STAT3Tyr705 phosphorylation, total STAT3, and ACTIN protein levels from the hypothalamus. (B) Ratio of signal intensities of pSTATTyr705
to total STAT3.
(C–F) DIOmice were treated with Celastrol (100 mg/kg) or vehicle by i.p. injection daily for 4 days. (C) POMC, (D) AGRP, (E)NPY, and (F) SOCS3mRNA expression
in the hypothalamus.
(G–I) DIO mice were administered with Celastrol (100 mg/kg) or vehicle (i.p., daily) for 3 days. On the fourth day, 100 or 250 mg/kg of Celastrol or vehicle
was administered 6 hr before the hypothalamus was collected. (G) The quantified ratio of the signals of phosphorylated PERK (Thr980) to total PERK of
the hypothalamus samples from four independent experiments in Figures S3A–S3H. (H) SERCA2B and TUBULIN protein levels and (I) quantified signal intensity
of SERCA2B to TUBULIN. Results in (G–I) were independently reproduced in four different cohorts.
Error bars are represented as mean ± SEM. p values were determined by one-way ANOVA (B), two-way ANOVA (G), and Student’s t test (*p < 0.05, **p < 0.01,
***p < 0.001). See also Figures S3 and S4.activity in the Celastrol-treated group during the dark cycle is
due to decreased food-searching behavior.
Metabolic parameters were also measured in lean mice.
EE in the dark cycle was slightly but significantly reduced in
Celastrol-treated lean mice (Figure 7D). Relative to vehicle-treat-
ment, Celastrol administration did reduce the RER values during
the dark phase (Figure 7E). Furthermore, Celastrol led to a
significant reduction in their physical activity in the dark cycle
compared to the control group (Figure 7F). We also analyzedhow Celastrol treatment affected the ob/ob and db/db mouse
models. Surprisingly, acute administration of Celastrol to ob/ob
mice led to a slight yet significant reduction in EE in both
cycles (Figure 7G). RER values were also significantly reduced
in the dark phase (Figure 7H), which was accompanied by a
reduction of physical activity (Figure 7I). EE was also significantly
reduced in Celastrol-treated db/db mice (Figure 7J). However,
RER values and physical activity were not altered in the db/db
mice (Figures 7K and 7L). The above metabolic chamberCell 161, 999–1011, May 21, 2015 ª2015 Elsevier Inc. 1007
A B C
D E F
G H I
J K L
Figure 7. Effect of Celastrol on Metabolic
Measures
(A–C) DIO mice, (D and E) lean, (G–I) ob/ob, or (J–L)
db/db mice were placed into metabolic cages and
received Celastrol (100 mg/kg) or vehicle once a day
for 3 days. (A, D, G, J) Energy expenditure, (B, E,
H, K) respiratory exchange ratios (RER; VCO2/VO2),
and (C, F, I, L) ambulatory count (physical activity)
from each group of mice are shown. Bar graphs
represent average of two dark (24–36 and 48–60 hr)
and two light cycles (12–24 and 36–48 hr). Data
represented in Figures 7A–7C are average of three
independent cohorts. (For DIO mice, n = 16 for
vehicle and n = 13 for Celastrol). For data and
analysis for Figures 7A–7C, see Data S2. Data rep-
resented in Figures 7D–7F are average of two inde-
pendent cohorts (n = 8 for vehicle and Celastrol). For
ob/obmice, n = 4 for vehicle and Celastrol; for db/db
mice, n = 4 for vehicle and Celastrol. Error bars
are represented as mean ± SEM. p values were
determined by Student’s t test (*p < 0.05, **p < 0.01,
***p < 0.001). See also Figures S5 and S6.measurements were obtained following 12–60 hr of Celastrol
treatment. Because plasma leptin levels in DIO mice return
to almost normal levels following chronic Celastrol treatment,
we made additional metabolic chamber measurements after
chronic (3 weeks) vehicle or Celastrol administration. Analysis
of EE, RER, and physical activity in DIO mice showed no differ-
ences during the third week of treatment (Figures S5A–S5C). In
addition, such chronic treatment also yielded no differences in
EE, RER, or the physical activity of lean, ob/ob, or db/db (Figures
S5D–S5L) mice.
We next compared the metabolic profiles of Celastrol-treated
DIO mice and their pair-fed, vehicle-treated controls. Vehicle-
treated DIO mice were subdivided into two groups; the first
was allowed to eat ad libitum (vehicle group), while the other
was pair fed with the Celastrol group (pair-fed group). Figure S6A
shows that, during the 3-day period when pair-feeding experi-
ments were performed, the average daily food intake of the
Celastrol mice was the same as for the pair-fed groups. Treat-1008 Cell 161, 999–1011, May 21, 2015 ª2015 Elsevier Inc.ment of DIO mice with Celastrol did not
alter the EE in the dark cycle, and there
were no differences among the three
groups in the dark cycle (Figure S6B
and Data S2 and S3). In the light cycle,
EE of Celastrol-treated mice showed a
slight, but not significant, increase when
compared with the vehicle-treated group.
However, the Celastrol-treated group had
significantly higher EE than the pair-fed
group in the light cycle (Figure S6B and
Data S2 and S3). RER values were signifi-
cantly decreased in the Celastrol-treated
group compared to both vehicle and
pair-fed groups in both dark and light cy-
cles. However, the pair-fed groups’ RER,
when compared to the vehicle-treated con-
trol group, did not show any alterations(Figure S6C and Data S2 and S3). The physical activity of the
Celastrol-treated mice was again significantly lower than the
vehicle-treated group (Figure S6D and Data S2 and S4), but no
reduction in physical activity was seen for the pair-fed group
(Figure S6D and Data S2 and S4). Importantly, the Celastrol-
treated group underwent significantly greater weight loss than
did the vehicle-treated and pair-fed groups (Figure S6E).
We next analyzed the liver from themice that were treated with
either vehicle or Celastrol for 3 weeks and documented that
livers of DIOmice treated with Celastrol were virtually non-differ-
entiable from sections taken from the lean mice (Figure S6F),
which indicates that Celastrol treatment in DIO mice also leads
to elimination of hepatic steatosis.
Plasma levels of alanine transaminase (ALT) and aspartate
aminotransferase (AST) (Figure S6H and S6I) showed significant
reductions in both groups, pointing to improved liver function.
Furthermore, total plasma cholesterol level was significantly
decreased in Celastrol-treated DIO mice (Figure S6J). Plasma
levels of triiodothyronine (T3) in vehicle- and Celastrol-treated
DIO mice documented that T3 levels were decreased and
indicated that Celastrol does not induce hyperthyroidism
(Figure S6K).
Celastrol Enhances Glucose Homeostasis in DIO Mice
We next investigated whether Celastrol can also improve
glucose homeostasis in DIO mice. Following treatment of
DIO mice with vehicle or Celastrol for 1 week, we performed a
glucose tolerance test (GTT). Clearance of glucose from the cir-
culation during GTT was significantly faster in Celastrol-treated
mice than in the vehicle-treated mice (Figures S7A and S7B).
Two weeks of Celastrol treatment also improved insulin sensi-
tivity in DIO mice, which was analyzed by an insulin tolerance
test (ITT) (Figures S7C and S7D). The blood glucose level at
6 hr fasting was also significantly lower in the Celastrol-treated
mice compared to the vehicle-treated group (Figure S7E).
When blood glucose levels of Celastrol-treated DIO mice were
compared to those in the pair-fed group, the Celastrol-treated
mice had significantly lower levels (Figure S6G). In addition,
plasma insulin levels were significantly decreased in Celastrol-
treated DIO mice relative to the control group (Figure S7F).
Analysis of glucose tolerance in lean mice showed a signifi-
cant improvement following 1 week of Celastrol treatment
(Figures S7G and S7H). But we did not detect any differences
in ITT (Figures S7I and S7J), 6 hr fasting blood glucose levels
(Figure S7K), or plasma insulin levels (Figure S7L) in vehicle-
versus Celastrol-treated lean mice. Celastrol treatment at
this dose (100 mg/kg) in db/db or ob/ob mice did not lead to
improvement in any of the parameters (Figures S7M–S7X).
DISCUSSION
Organisms that had developed powerful mechanisms to store
energy and use it efficiently have likely passed through a strin-
gent natural selection process during evolution (Dietrich and
Horvath, 2013; Friedman, 2009; Myers et al., 2010). Correspond-
ingly, systems that have evolved to communicate the amount of
energy stored in the body to the brain are among themost critical
for surviving in nature. Leptin was the first and most powerful
hormone identified in relation to the control of energy meta-
bolism and to communicating information about peripheral en-
ergy sufficiency to the brain. Reduction in the physiological
concentrations of circulating leptin in a starvation state creates
a very powerful stimulus for food consumption and signals a
need for the body to increase its energy stores and, at the
same time, to reduce energy expenditure for multiple physiolog-
ical functions. Indeed, the ob/ob and db/dbmouse models, all of
which lack leptin action, develop morbid obesity due to severely
increased food intake and reduced energy expenditure (Cole-
man, 1978).
Despite very high concentrations of leptin in the circulation
in obesity, the hormone can neither suppress food intake nor
increase energy expenditure. Instead, obesity is characterized
by hyperphagia and reduced energy expenditure, reminiscent
of a leptin-deficient condition (Friedman, 2004). These observa-
tions led to the notion that obesity is a leptin-resistant condition.
But the absence of definitive evidence on the effectiveness ofusing high levels of circulating leptin to treat obesity has created
a long-standing debate about whether or not the condition of
leptin resistance actually exists.
Here, we have used an unconditional in silico screening
approach to look for small molecules that increase leptin
sensitivity. We developed this strategy primarily based on our
previous observations that increased hypothalamic ER stress
is a major causative factor in the development of leptin resis-
tance and obesity. ER stress signaling is highly complex and
one of the most central signaling pathways in the cell. Consid-
ering that the targeting of single molecules for treatment of
obesity has failed to lead to the discovery of effective obesity
drugs, we did not try to target the ‘‘usual suspects’’ (such as
JNK, ATF4, or others) in the ER stress pathway. Instead, we
focused primarily on homeostatic ER conditions, which were
specifically established on a previous condition that was
characterized with ER stress. As such, we used a variety of
tissues and a number of different manipulations to reduce ER
stress and determined the outcome of these manipulations in
terms of gene expression profiling. We then used these expres-
sion profiles to search for small molecules, which have the ability
to create the same expression profiles. However, considering
the different possibilities in gene expression profiles of reduced
ER stress conditions, we did not use the basic enrichment
scores provided by CMAP but added another component to
the analysis by converting these enrichment scores to absolute
enrichment scores for the analysis. Furthermore, subsequently,
another layer was added to this initial analysis: we used all of
the absolute enrichment scores to determine the small molecule
that had the highest score in terms of its similarity to all six
expression profiles that were used in the screening. Celastrol
again had the highest score, with a high distance to all the other
molecules in the CMAP database.
A true leptin sensitizer should, above all, be effective in
hyperleptinemic and leptin-resistant DIO mice and should have
minimal or no effects in lean, ob/ob, or db/dbmice. Furthermore,
a putative leptin sensitizer should reduce food intake and
should not lead to a reduction in energy expenditure, as seen
in starvation conditions, and its effect should gradually diminish
as the obese mice lose weight and leptin levels return to normal.
Celastrol meets all of these specifications. While administration
of Celastrol to hyperleptinemic and leptin-resistant DIO mice
was effective in decreasing food consumption and in reducing
body weight by up to 45%, minimal effects were noted in the
food intake and body weight of lean mice or of ob/ob and
db/db mice. Despite the major reductions in food intake and,
consequently, in the body weight of Celastrol-treated DIO
mice, lean mass in these animals was not altered, which is
consistent with the notion that leptin-induced anorexia does
not cause a reduction in lean mass (as opposed to starvation-
caused weight loss) (Halaas et al., 1995). More interestingly,
Celastrol treatment in obese mice significantly decreased RER
values relative to the vehicle-treated obese controls or the
pair-fed group, further indicating the increase in leptin sensitivity.
All of these results provide evidence in support of a role for
Celastrol in reducing obesity by increasing leptin sensitivity.
Additional evidence that Celastrol is a leptin sensitizer comes
from experiments in which we analyzed the physiological andCell 161, 999–1011, May 21, 2015 ª2015 Elsevier Inc. 1009
biochemical responses to exogenous leptin administration. Our
hypothesis for the ineffectiveness of Celastrol in lean mice was
the low levels of circulating leptin in this model. If this hypothesis
is correct, increasing the circulating levels of leptin acutely in
Celastrol-pretreated lean mice should have a greater effect
than in a control group. Indeed, this was the case: we found
that, when Celastrol-pretreated lean mice were injected with
leptin, food consumption and body weight were both signifi-
cantly reduced relative to the vehicle-pretreated mice. Further-
more, despite the fact that Celastrol already utilizes the high
levels of endogenous leptin, administration of a bolus dose of
leptin also leads to a greater reduction in body weight of
leptin-resistant DIO mice. And finally, in addition to these direct
physiological responses, Celastrol also augmented the phos-
phorylation of STAT3Tyr705 in the hypothalamus, an effect that
was further enhanced by leptin injection.
Taken together, these observations document that Celastrol
is a leptin sensitizer and clearly point to the existence of leptin
resistance in obesity. The findings also make a strong case for
the therapeutic potential of increasing the sensitivity of obese
states to leptin.
How does Celastrol create the leptin-sensitizing effect? We
do not have a single molecule-based mechanistic explanation
at the moment. Celastrol can be discovered by analyzing the
effects of XBP1S and of the chemical chaperones (4-PBA
and TUDCA); the findings were further enriched with the differ-
ential gene expression profile of the hypothalamus in DIO mice.
Indeed, Celastrol significantly reduces PERK phosphorylation
and SERCA2B protein levels, which all strongly indicates that
ER stress is reduced and provides a direct mechanistic link
between Celastrol, ER stress, and leptin sensitization.
In addition, Celastrol has been shown to inhibit HSP90.
HSP90 is one of the most abundant proteins in the cell, and
high levels of Celastrol were previously shown to inhibit
HSP90. However, the doses that we used in mice do not inhibit
HSP90, and HSP90 inhibition in our experimental setting is
irrelevant for a mechanistic explanation for Celastrol action.
Also, it has been suggested that high doses of Celastrol
block NF-kB activity (Lee et al., 2006); however, analysis of
the NF-kB target genes did not show any alterations nor did
we observe any treatment-related increases in the levels of
several genes that are also the target NF-kB (data not shown).
While further studies are needed to unravel the exact mecha-
nism of action(s) of Celastrol in increasing leptin sensitivity,
the results that we obtained thus far clearly indicate that
Celastrol’s anti-obesity action cannot be attributed to either
HSP90 or NF-kB inhibition.
Our approach in this study did not involve drug screening
based on the targeting of single molecules. Rather, our experi-
mental strategy was motivated by the long years of failure
in finding a treatment for obesity by a single target-based
screening. Our use of an unconditional alternative approach
has uncovered a very potent anti-obesity molecule.
The effect of Celastrol is more potent than reported for bariat-
ric surgery in mice, with which weight loss is around 35%–40%
(Liou et al., 2013; Mokadem et al., 2014; Ryan et al., 2014).
Obesity affects more people worldwide than any other debili-
tating disease. If Celastrol works in humans the way that it1010 Cell 161, 999–1011, May 21, 2015 ª2015 Elsevier Inc.does in mouse models, the outcome could be an effective ther-
apeutic approach for treatment of obesity.
EXPERIMENTAL PROCEDURES
Whole-Genome Gene Expression Studies
For liver whole-genome gene expression study, 10-week-old lean male and
10-week-old ob/ob male mice orally received either saline (n = 3 for each
group) or 4-PBA (n = 3 for each group; 1 g/kg, twice a day in 0.5 g/kg for
10 days). After 10-day treatment, the liver was extracted and flash frozen in
liquid nitrogen. Another group of 10-week-old ob/ob male mice were injected
with 1 3 108 pfu (per g body weight) of adenoviruses that express b-galacto-
sidase (Ad-LacZ) or mouse XBP1S (Ad-XBP1S) via the tail vein (n = 3 for each
group). One week after injection, all mice were fasted for 6 hr and the liver was
extracted and stored in 80C until further processing.
For hypothalamus whole-genome gene expression study, hypothalami of
DIO mice fed with HFD for 20 weeks and age-matched lean mice fed with
chow diet for 20 weeks were collected and stored in 80C for later process-
ing (n = 4 for each group). In another experiment, DIO mice fed with HFD for
16 weeks were administered with either saline, 4-PBA (1 g/kg/day), or TUDCA
(150 mg/kg/day) for 7 days, and their hypothalami were collected, flash frozen
in liquid nitrogen, and stored in 80C before processing.
RNAs from the liver of mice that were treated with vehicle or 4-PBA were
analyzed on Illumina MouseRef-8 Expression BeadChips. RNA samples
from the liver of mice that were injected with Ad-LacZ or Ad-XBP1S were
analyzed on Affymetrix GeneChipMouseGenome 430 2.0 Array. RNA samples
from the hypothalamus of lean and DIO mice were analyzed on Affymetrix
Mouse Gene 1.0 ST Array.
The microarray data obtained from experiments described above were
used as queries for Connectivity Map (CMAP) after conversion into human
homologs, and detailed processes are described in the Supplemental
Experimental Procedures.
Metabolic Chamber Measurements
Metabolic parameters of all mouse models (lean, DIO, ob/ob and db/db)
were determined by using Columbus Instruments Comprehensive Lab Animal
Monitoring System (CLAMS). Further experimental details can be found in the
Supplemental Experimental Procedures, and raw data for energy expenditure
(EE), respiratory exchange ratio (RER), and ambulatory activity (X-Amb) can be
found in Data S3 and S4.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four data files and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2015.05.011.
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